Moreover, downregulation of EZH2 or BRCA1 sensitized A2780/DDP cells to cisplatin, which contradicts BRCA1’s tumor-suppressing role but is in line with the concept that its upregulation is associated with DNA repair-mediated resistance to cisplatin [103]. This evidence concerns the gene EZH2 and neoplasm.